home / stock / idya / idya quote
Last: | $ |
---|---|
Change Percent: | 1.34% |
Open: | $6.60 |
Close: | $6.82 |
High: | $6.95 |
Low: | $6.60 |
Volume: | 34,610 |
Last Trade Date Time: | 02/12/2020 04:41:43 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $6.60 | $6.82 | $6.95 | $6.60 | 34,610 | 02-12-2020 |
$ | $6.45 | $6.73 | $6.93 | $6.45 | 37,374 | 02-11-2020 |
$ | $7.12 | $6.73 | $7.50 | $6.6701 | 88,441 | 02-10-2020 |
$ | $8.21 | $7.19 | $8.50 | $6.40 | 107,834 | 02-07-2020 |
$ | $8.60 | $8.18 | $8.60 | $8.18 | 15,826 | 02-06-2020 |
$ | $9.02 | $8.60 | $9.10 | $8.19 | 51,778 | 02-05-2020 |
$ | $9.08 | $8.71 | $9.25 | $8.32 | 42,535 | 02-04-2020 |
$ | $8.55 | $9.06 | $9.06 | $8.55 | 32,084 | 02-03-2020 |
$ | $8.60 | $8.55 | $8.84 | $8.55 | 8,783 | 01-31-2020 |
$ | $8.48 | $8.60 | $8.89 | $8.42 | 39,346 | 01-30-2020 |
$ | $9.15 | $8.50 | $9.17 | $8.42 | 211,576 | 01-29-2020 |
$ | $9.00 | $9.05 | $9.0554 | $8.82 | 6,445 | 01-28-2020 |
$ | $9.09 | $8.80 | $9.09 | $8.3501 | 30,531 | 01-27-2020 |
$ | $8.99 | $9.05 | $9.29 | $8.90 | 14,241 | 01-24-2020 |
$ | $9.39 | $9.30 | $9.39 | $8.395 | 39,250 | 01-23-2020 |
$ | $9.81 | $9.43 | $10.11 | $9.43 | 49,543 | 01-22-2020 |
$ | $9.90 | $9.70 | $10.20 | $9.70 | 34,768 | 01-21-2020 |
$ | $10.04 | $10.03 | $10.25 | $9.68 | 75,190 | 01-20-2020 |
$ | $10.04 | $10.03 | $10.25 | $9.68 | 75,190 | 01-17-2020 |
$ | $10.85 | $10.04 | $10.9638 | $9.55 | 68,468 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...